Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q2 2021 Earnings Presentation
11 slides from Adc Therapeutics Sa's earnings presentation, Aug 3, 2021
Slide 1: Innovating Science. Inspiring Hope. 2Q 2021 Results
Innovating Science. Inspiring Hope. 2Q 2021 Results August 3, 2021
Slide 2: Forward-looking statements
Forward-looking statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda 01 Chris Martin Introduction Chief Executive Officer Jennifer Herron Commercial Highlights 02 Chief Commercial Officer Jay Feingold Clinical Highlights 03 Chief Medical Officer Jenn Creel Financial Update 04 Chief Financial Officer 3
Slide 4: Recent Highlights
Recent Highlights ZYNLONTATM (loncastuximab tesirine-lpyl) § Encouraging initial launch demand driven by strong execution of differentiated product profile in an area of high unmet medical need § Update from Phase 2 LOTIS-2 trial at ASCO and ICML: median DoR increased to 13.4 months, no new safety s
Slide 5: Encouraging Start to ZYNLONTA Launch
Encouraging Start to ZYNLONTA Launch … … Positive reception Significant increase from both academic in aided and unaided Net sales and community- product awareness of $3.8 million based centers since launch Engaged with Substantial number Seamless hybrid launch all key commercial of orders from NCCN
Slide 6: Expanding the Potential for ZYNLONTA
Expanding the Potential for ZYNLONTA Additional trials in 2021 § Pivotal Ph 2 trial in FL – open for enrollment LOTIS-5 § Dose-finding study of ZYNLONTA in combination ZYNLONTA with R-CHOP in 1L DLBCL + rituximab § ZYNLONTA in multiple combinations in NHL § Ph 3 trial in combination with rituximab L
Slide 7: Cami Clinical Programs Advancing
Cami Clinical Programs Advancing Novel ADC targeting CD25 and regulatory T cells (Tregs) Relapsed or refractory Hodgkin lymphoma Advanced solid tumors § Phase 2 pivotal trial enrollment complete (117 § Phase 1b dose escalation trial of Cami + patients) with ongoing 12-month follow-up pembrolizumab o
Slide 8: Solid Tumor Franchise Leverages Validated ADC Platform
Solid Tumor Franchise Leverages Validated ADC Platform Cami ADCT-901 ADCT-601 Targeting CD25 Targeting KAAG-1 Targeting AXL § Phase 1b dose escalation § Targeting advanced solid § AXL overexpressed in many trial of Cami + tumors with high unmet solid tumors - lung, breast, pembrolizumab ongoing need
Slide 9: 2Q 2021 Financial Update (in $ millions)
2Q 2021 Financial Update (in $ millions) Balance Sheet June 30, 2021 March 31, 2021 Cash and cash equivalents $371.9 $383.1 Statement of Cash Flows 2Q 2021 Net cash used for operating activities $58.0 3 Months Ended Statement of Operations June 30 2021 2020 Research & Development Expenses $39.5 $26.
Slide 10: Anticipated Development Milestones
Anticipated Development Milestones ZYNLONTA § 2H 2021: § Initiate first line dosing trial of ZYNLONTA with R-CHOP § Initiate ZYNLONTA trial in multiple combinations in NHL § Complete safety lead-in of the Phase 3 LOTIS-5 confirmatory trial in combination with rituximab § Continue enrollment in Phase
Slide 11: Innovating Science. Inspiring Hope.
Innovating Science. Inspiring Hope. 2Q 2021 Results